Bitolterol

Bitolterol mesylate, formerly sold under the brand name Tornalate, is a short-acting β₂-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma^[1][2] and chronic obstructive pulmonary disease (COPD).^[3][4][5] Bitolterol relaxes the smooth muscles present continuously around the bronchi and bronchioles facilitating the flow of air through them.

Trade namesTornalate

AHFS/Drugs.comMicromedex Detailed Consumer Information

MedlinePlusa601236

ATC code

• R03AC17 (WHO)

Quick facts Clinical data, Trade names ...

Bitolterol

Clinical data
Trade names	Tornalate
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a601236
ATC code	R03AC17 (WHO)
Legal status
Legal status	US: Discontinued
Pharmacokinetic data
Onset of action	2–5 minutes
Duration of action	6–8 hours
Identifiers
IUPAC name (RS)-[4-(1-Hydroxy-2-tert-butylamino-ethyl)-2-(4-methylbenzoyl)oxy-phenyl] 4-methylbenzoate
CAS Number	30392-40-6 mesylate: 30392-41-7 Y
PubChem CID	35330
DrugBank	DB00901
ChemSpider	32525
UNII	9KY0QXD6LI mesylate: 4E53T3611U Y
KEGG	D07534 Y mesylate: D00684 Y
ChEMBL	ChEMBL1201295 Y
CompTox Dashboard (EPA)	DTXSID1022683
Chemical and physical data
Formula	C28H31NO5
Molar mass	461.558 g·mol−1
3D model (JSmol)	Interactive image
Chirality	Racemic mixture
SMILES O=C(Oc2cc(ccc2OC(=O)c1ccc(cc1)C)C(O)CNC(C)(C)C)c3ccc(cc3)C

Close

Bitolterol is a prodrug of colterol.^[6][7] It has a rapid onset of action (2–5 minutes) and may last up to 6–8 hours.^[8] The drug, alone or in co-administration with theophylline, doesn't show cardiotoxic effect.^[9]

The US Food and Drug Administration (FDA) approved bitolterol in December 1984. The drug was withdrawn from the market by Élan Pharmaceuticals in 2001.